Literature DB >> 17987283

New technologies around biomarkers and their interplay with drug development.

Frank Dieterle1, Estelle Marrer.   

Abstract

What conductors are to their orchestras, biomarkers are to their associated technologies. Building fundamental science, supporting early diagnosis of diseases and following their progression, improving efficacy and safety of treatments, optimizing patient selection and adapting dosing of drugs, helping decide which therapy is most appropriate; these are examples of a few contexts in which biomarkers are key players. Technology development can definitely not escape being associated with these steps. In other words, today's biomarkers are the thermometers of tomorrow's therapies. This review provides an overview of recently established platforms as well as new and upcoming technologies for biomarker development in the context of drug development. The roles as well as the pros and cons of different disciplines such as genetics, genomics, proteomics, metabonomics, and assay development will be discussed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17987283     DOI: 10.1007/s00216-007-1688-y

Source DB:  PubMed          Journal:  Anal Bioanal Chem        ISSN: 1618-2642            Impact factor:   4.142


  4 in total

1.  Biomarkers intersect with the exposome.

Authors:  Stephen M Rappaport
Journal:  Biomarkers       Date:  2012-06-07       Impact factor: 2.658

Review 2.  Immunoaffinity capillary electrophoresis as a powerful strategy for the quantification of low-abundance biomarkers, drugs, and metabolites in biological matrices.

Authors:  Norberto A Guzman; Timothy Blanc; Terry M Phillips
Journal:  Electrophoresis       Date:  2008-08       Impact factor: 3.535

Review 3.  Biomarkers of immunotoxicity for environmental and public health research.

Authors:  Paurene Duramad; Nina T Holland
Journal:  Int J Environ Res Public Health       Date:  2011-05-06       Impact factor: 3.390

4.  Differential protein expression in human corneal endothelial cells cultured from young and older donors.

Authors:  Cheng Zhu; Ian Rawe; Nancy C Joyce
Journal:  Mol Vis       Date:  2008-09-30       Impact factor: 2.367

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.